EXPAREL®, a multi-vesicular liposome injectable suspension of bupivacaine, was initially developed by Skyepharma and the development was completed by Pacira Pharmaceuticals following the sale of Skyepharma’s injectable business.


This amide local anaesthetic is indicated for single-dose infiltration into the surgical site to produce extended postsurgical analgesia. The product is marketed by Pacira Pharmaceuticals in the US.

> Find out more

Skyepharma receives a share of the net sales of the product.

Disclaimer Masterpage